Paper Details

  1. Home
  2. Paper Details

Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.

Author: DwivediS, KoiralaS, RijalS, SangraulaH, SharmaK K

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Currently, there are no effective oral treatments for visceral leishmaniasis, a parasitic disease affecting about 0.5 million people annually. Miltefosine, originally developed as an antitumor agent, has shown promise as an oral treatment for visceral leishmaniasis. Sitamaquine, an 8-aminoquinoline, is another potential oral treatment for visceral leishmaniasis.
Paper Details　
Original Abstract of the Article :
Currently there are no effective orally administered drugs or visceral leishmaniasis or kala-azar, a parasitic disease affecting about 0.5 million people a year, majority of whom are in India and adjacent areas of Nepal. Symptoms of affected patients are fever, cachexia, hepatosplenomegaly and pancy...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/14621038

データ提供：米国国立医学図書館（NLM）

New Hope for Treating Kala-azar: Orally Effective Drugs

Kala-azar, also known as visceral leishmaniasis, is a serious parasitic disease that affects the internal organs, primarily the spleen, liver, and bone marrow. This study focuses on the development of orally effective drugs for treating kala-azar, a significant advancement over traditional injectable treatments. The researchers highlight the promising potential of miltefosine and sitamaquine as new oral therapies for this disease.

Oral Treatment Options for Kala-azar

The study describes the success of miltefosine, an oral drug originally developed for cancer treatment, in achieving high cure rates in patients with kala-azar. It also discusses the promising results of clinical trials for another oral drug, sitamaquine, which has shown potential as a treatment for kala-azar. These findings offer hope for developing more convenient and accessible treatment options for this neglected disease.

Improving Access to Treatment for Neglected Diseases

This research is important for patients suffering from kala-azar, especially in developing countries where the disease is prevalent. The development of orally effective drugs can significantly improve access to treatment, reduce healthcare costs, and improve patient outcomes. It highlights the importance of continued research and investment in neglected diseases to ensure everyone has access to effective and affordable treatment.

Dr.Camel's Conclusion

Just as a camel relies on its resilience to survive the harsh desert, individuals with kala-azar require innovative and accessible treatment solutions. This study offers hope for the future of kala-azar treatment, underscoring the importance of research and development to ensure everyone has access to effective medical care. By working together, we can bridge the gap in healthcare access and bring relief to those in need, allowing them to thrive despite the challenges they face.

Date :
  1. Date Completed 2004-06-14
  2. Date Revised 2014-11-20
Further Info :

Pubmed ID

14621038

DOI: Digital Object Identifier

14621038

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.